Dr. Katherine Tarlock, a pediatric hematology expert from Seattle Children’s Hospital briefly discusses AML and its prevalence in children. She will discuss how it is diagnosed, symptoms associated and the possible treatment options for children. This will include watch and wait , medications and bone marrow transplant. Dr. Tarlock concludes with tips for parents regarding follow up care.
- Learn about the short and long term effects of treatment (i.e. fertility preservation if patient is a BMT candidate, etc.)
- Understand the relationship between MDS and AML
- Learn about current and experimental therapies
- Learn questions that you can ask your child’s healthcare team in taking charge of their care.
Katherine Tarlock, MD
Dr. Katherine Tarlock earned her medical degree from Rosalind Franklin University in 2008. She then completed her residency in Pediatrics at Lucile Packard Hospital, Stanford University School of Medicine. She then went on to a fellowship in Pediatric Hematology & Oncology at Seattle Children’s Hospital/Fred Hutchinson Cancer Research Center in Seattle, and she completed her training in 2014. Following completion of her training, Dr. Tarlock joined the faculty at Seattle Children’s Hospital in the division of Hematology/Oncology and continued her research at the Fred Hutchinson Cancer Research Center. She is board certified in Pediatrics and Pediatric Hematology & Oncology. Dr. Tarlock’s clinical and research focus are centered in acute myeloid leukemia and myeloid diseases. She is particularly interested in genomic mutations that are involved in development of leukemia and may predict responses to therapy, as well as development of new therapies for acute myeloid leukemia, including immunotherapeutic strategies. She is also a member of the Children’s Oncology Group Myeloid Disease Committee.
This webinar is brought to you by The Aplastic Anemia and MDS International Foundation with support from Celgene, Takeda and Agios, and promotional support from The Leukemia & Lymphoma Society.
For any questions or comments about this program, please email feedback@LLS.org.